PRAC meeting highlights 4-7 April 2022
04/04/2022
Medicines for human use
Pharmacovigilance risk assessment committee (PRAC)
The European Medicines Agency's Pharmacovigilance Risk Assessment Committee (PRAC) is responsible for assessing and monitoring safety issues for human medicines.
The current PRAC highlights from the April 2022 meeting highlights insufficient evidence linking mRNA COVID-19 vaccines with autoimmune hepatitis.